Search Results - "Campogan, Dwayne"

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens by Derby, Nina R, Gray, Sean, Wayner, Elizabeth, Campogan, Dwayne, Vlahogiannis, Giorgos, Kraft, Zane, Barnett, Susan W, Srivastava, Indresh K, Stamatatos, Leonidas

“…Abstract Eleven anti-HIV Env monoclonal antibodies (MAbs) were isolated from mice immunized with soluble Env proteins derived from the clade B Env, SF162, or…”
Get full text

PD14-07 REAL-TIME IMAGING DEMONSTRATING T-CELL MEDIATED DESTRUCTION OF PROSTATIC ACID PHOSPHATASE (PAP)-EXPRESSING CELLS IN PATIENTS (PTS) TREATED WITH SIPULEUCEL-T (SIP-T) by Inman, Brant, Vu, Tuyen, Yu, Evan Y, Campogan, Dwayne, Haynes, Heather, Sheikh, Nadeem A, George, Daniel

Get full text

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival by Antonarakis, Emmanuel S, Small, Eric J, Petrylak, Daniel P, Quinn, David I, Kibel, Adam S, Chang, Nancy N, Dearstyne, Erica, Harmon, Matt, Campogan, Dwayne, Haynes, Heather, Vu, Tuyen, Sheikh, Nadeem A, Drake, Charles G

“…Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit…”
Get full text

Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) by Drake, Charles G., Antonarakis, Emmanuel S., Petrylak, Daniel Peter, Quinn, David I., Kibel, Adam S., Chang, Nancy N., Dearstyne, Erica, Campogan, Dwayne, Haynes, Heather, Vu, Tuyen, Sheikh, Nadeem Anwar, Small, Eric Jay

“…Abstract only…”
Get full text

Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) by Antonarakis, Emmanuel S., Quinn, David I., Kibel, Adam S., Petrylak, Daniel Peter, Vu, Tuyen, Campogan, Dwayne, Chang, Nancy N., Trager, James B., Sheikh, Nadeem Anwar, Drake, Charles G.

“…Abstract only 162 Background: Sip-T is an FDA-approved immunotherapy for patients (pts) with asymptomatic or minimally symptomatic metastatic CRPC. Sip-T is…”
Get full text

Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Beer, Tomasz M., Corman, John, Lance, Raymond S., Campogan, Dwayne, Vu, Tuyen, Haynes, Heather, Chang, Nancy N., Sheikh, Nadeem Anwar, Curti, Brendan D.

“…Abstract only 196 Background: Sip-T, an autologous cellular immunotherapy for asymptomatic/minimally symptomatic mCRPC, induces immune responses to target…”
Get full text

Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC) by Small, Eric Jay, Fong, Lawrence, Quinn, David I., Drake, Charles G., Campogan, Dwayne, Vu, Tuyen, Sheikh, Nadeem Anwar, Chang, Nancy N., Petrylak, Daniel Peter

“…Abstract only…”
Get full text

Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) by Drake, Charles G., Antonarakis, Emmanuel S., Petrylak, Daniel Peter, Quinn, David I., Kibel, Adam S., Chang, Nancy N., Dearstyne, Erica, Campogan, Dwayne, Haynes, Heather, Vu, Tuyen, Sheikh, Nadeem Anwar, Small, Eric Jay

“…Abstract only 5046 Background: Sip-T is an FDA-approved autologous cellular immunotherapy for patients with asymptomatic or minimally symptomatic metastatic…”
Get full text

Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses by Drake, Charles G., Petrylak, Daniel Peter, Antonarakis, Emmanuel S., Kibel, Adam S., Chang, Nancy N., Vu, Tuyen, Campogan, Dwayne, Haynes, Heather, Trager, James B., Sheikh, Nadeem Anwar, Quinn, David I.

“…Abstract only 163 Background: Sip-T is an FDA-approved immunotherapy for treating patients (pts) with asymptomatic or minimally symptomatic metastatic…”
Get full text

Sipuleucel-T (sip-T)–induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC) by Antonarakis, Emmanuel S., Quinn, David I., Kibel, Adam S., Petrylak, Daniel Peter, Vu, Tuyen, Campogan, Dwayne, Chang, Nancy N., Cummings, Crystal, Trager, James B., Chinn, Jason, Sheikh, Nadeem Anwar, Drake, Charles G.

“…Abstract only…”
Get full text

Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence by Bajorin, Dean F., Gomella, Leonard G., Sharma, Padmanee, Plimack, Elizabeth R., O'Donnell, Peter H., Hoffman-Censits, Jean H., Flaig, Thomas W., Quinn, David I., Campogan, Dwayne, Haynes, Heather, McCoy, Candice, Maher, Johnathan, DeVries, Todd, Sheikh, Nadeem A., Lerner, Seth P.

“…Abstract only…”
Get full text

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T by Drake, Charles G, Quinn, David, Dreicer, Robert, Antonarakis, Emmanuel, Shore, Neal, Corman, John, Concepcion, Raoul, Pieczonka, Christopher, Campogan, Dwayne, Fan, Li-Qun, Chang, Nancy, Sheikh, Nadeem, Petrylak, Daniel

Get full text

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) by Drake, Charles G, Quinn, David, Dreicer, Robert, Antonarakis, Emmanuel, Shore, Neal, Corman, John, Concepcion, Raoul, Pieczonka, Christopher, Campogan, Dwayne, Fan, Li-Qun, Chang, Nancy, Sheikh, Nadeem, Petrylak, Daniel

“…BackgroundP12-2 (STRIDE; NCT01981122) is an ongoing, randomized, Phase II, open-label study evaluating concurrent vs sequential administration of the androgen…”
Get full text